Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05820672 · ClinicalTrials.gov registry record
A US Non-interventional, Effectiveness and Safety Study of Patients Treated With SKYTROFA
A clinical trial of Growth Hormone Deficiency, sponsored by Ascendis Pharma Endocrinology Division A/S.
- Recruiting
- Registry status
- 900
- Enrollment target
- 20
- Study locations
NCT05820672: Recruiting study of Growth Hormone Deficiency, sponsored by Ascendis Pharma Endocrinology Division A/S.
NCT05820672 is a study of Growth Hormone Deficiency that is actively recruiting participants, run by Ascendis Pharma Endocrinology Division A/S. The registered enrollment target is 900 participants, above the 331-participant average among 16 other Growth Hormone Deficiency trials with a reported enrollment target (172% higher). The trial reports 20 study locations across 15 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05820672, a study of Growth Hormone Deficiency, is actively recruiting participants, sponsored by Ascendis Pharma Endocrinology Division A/S.
- RECRUITING
- Registry status
- 900 participants
- Enrollment target
- 20
- Study locations
Study Summary
The goal of this study is to genrate evidence on long-term effectiveness and safety of SKYTROFA (lonapegsomatropin) in patients with growth hormone deficiency under routine clinical care
Primary Outcome
Incidence of Adverse Events and Serious Adverse Events
Conditions Studied
Interventions
- OTHER No intervention
Study Locations (20)
California
- Ascendis Investigational Site - Orange
- Ascendis Investigational Site - Sacramento
- Ascendis Investigational Site - San Francisco
Florida
- Ascendis Investigational Site - Orlando
- Ascendis Investigational Site - Orlando
- Ascendis Investigational Site - Tampa
New Hampshire
- Ascendis Investigational Site - Lebanon
- Ascendis Investigational Site - Manchester
Arizona
- Ascendis Investigational Site - Phoenix
Colorado
- Ascendis Pharma Investigational Site - Centennial
District of Columbia
- Ascendis Investigational Site - Washington D.C.
Georgia
- Ascendis Investigational Site - Sandy Springs
Idaho
- Ascendis Investigational Site - Boise
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 900 participants |
| Start Date | 2023-03-20 |
| Est. Completion | 2033-03 |
What NCT05820672 shows while recruiting
NCT05820672 is an observational study that tracks outcomes without assigning an intervention. The registered 900 participants enrollment target is mid-sized for trials with a published cap, above the 331-participant average among 16 other Growth Hormone Deficiency trials with a reported enrollment target (172% higher).
The record links to 1 condition, with Growth Hormone Deficiency appearing as the primary indexed condition, and to 1 intervention - of which No intervention is the first listed.
NCT05820672 names 20 study sites across 15 states, led by California, Florida, New Hampshire.
Frequently Asked Questions
What is clinical trial NCT05820672 about?
NCT05820672 is a clinical study titled "A US Non-interventional, Effectiveness and Safety Study of Patients Treated With SKYTROFA". The goal of this study is to genrate evidence on long-term effectiveness and safety of SKYTROFA (lonapegsomatropin) in patients with growth hormone deficiency under routine clinical care
What is the current status of trial NCT05820672?
This trial is currently recruiting. The enrollment target is 900 participants. The study started on 2023-03-20. Estimated completion is 2033-03.
What conditions does trial NCT05820672 study?
This clinical trial studies the following conditions: Growth Hormone Deficiency.
What interventions are being tested in trial NCT05820672?
The interventions under investigation include: No intervention (OTHER).
Who is sponsoring clinical trial NCT05820672?
This trial is sponsored by Ascendis Pharma Endocrinology Division A/S, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05820672 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Growth Hormone Deficiency
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05820672's enrollment target sits among peer trials
900 2nd of 16 the highest of 16 other Growth Hormone Deficiency trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Growth Hormone Deficiency trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Post-Authorisation Safety Study (PASS) of Patients Treated With Lonapegsomatropin
RECRUITING
-
Effects of GH and Lirglutide on AgRP
RECRUITING · Phase 4
-
Chromosome 18 Clinical Research Center
RECRUITING
-
Growth Hormone Replacement Therapy for Retried Professional Football Players
RECRUITING · Phase 2
-
Phase 2 Study of LUM-201 in Children Who Have Previously Completed the LUM-201-01 Trial (OraGrowtH213)
COMPLETED · Phase 2
-
Cardiovascular Risk in Growth Hormone Deficient Young Adult Males After Completing Growth Hormone Therapy
COMPLETED
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02352116 · 900 participants · NA
Evaluation of Post-PACU Pain Management in Pediatric Surgery
- NCT02414347 · 900 participants
F 18 T807 Tau PET Imaging of Alzheimer's Disease
- NCT02670408 · 900 participants
Diagnostic and Therapeutic Applications of Microarrays in Heart Transplantation
- NCT02960022 · 900 participants · Phase 2
A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI